Shortages of GLP-1 medications, like Ozempic and Wegovy, are common occurrences. These shortages will likely continue into the future and will make it hard for patients dealing with Type 2 diabetes and obesity to receive consistent treatment.
At the most recent meeting of the American Chemical Association, a research team presented their findings that could solve the GLP-1 shortage. They suggest that an improvement in GLP-1 drug delivery, a process they call “painting,” could reduce the amount of medication needed for effective treatment.
Improvements in Drug Delivery
In studies with mice, the research team, led by Bradley Pentelute, a professor of chemistry at MIT, found that their new drug delivery system resulted in sustained weight loss and extended blood sugar management. More significantly, only one-fourth of the typical dose of a GLP-1 injection was required to see these results.
